中國生物科技服務(08037.HK)與石藥(01093.HK)訂戰略合作意向書
中國生物科技服務(08037.HK)公佈,與石藥集團(01093.HK)訂立無法律約束力戰略合作意向書。雙方擬於意向書籤署後一年有效期內,尋求在下述以股權爲基礎的投資或公司已開展的項目上進行一項或多項戰略合作。
當中,倘若條件許可並符合所有監管要求及上市條例,石藥有意對公司進行10%至20%股權之直接股權投資。若成事,石藥將會被視爲公司戰略股東,可在整個產品商業化進程中,從生產、臨牀試驗、申報批準產品上市至銷售等領域,提供增值貢獻。
石藥擬對公司全資附屬公司鵬博(香港)中子癌症治療中心作出不少於20%股權直接股權投資,從而參與正在中國海南省設立的採用硼中子捕獲治療(BNCT)技術之癌症治療中心項目。
公司指,擬將正在研究和開發的製造SARS-CoV2重組亞單位疫苗的技術授權許可給石藥使用。石藥將會負責產品的規模化生產及市場推廣。石藥亦可支持間接非全資附屬上海隆耀的研發、 轉化、產品上市及銷售。若成事,一旦獲得相關監管機構批準產品上市, 石藥將擁有上海隆耀CAR-T產品的優先銷售權。
公司指,除上述擬合作事項外,石藥控股或參股的公司中,符合公司戰略定位和發展方向的,公司可在商業條件許可、通過內部審批及滿足相關條例時參與併購或投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.